Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has received a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $36.4615.

A number of brokerages have issued reports on JANX. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Piper Sandler cut their price objective on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Wolfe Research raised Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a research note on Monday. Guggenheim lowered their target price on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $18.60 on Thursday. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The firm has a market cap of $1.14 billion, a PE ratio of -11.34 and a beta of 2.50. The company has a 50-day moving average of $15.76 and a two-hundred day moving average of $14.67.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million for the quarter, compared to analyst estimates of $19.07 million. Sell-side analysts anticipate that Janux Therapeutics will post -1.76 EPS for the current fiscal year.

Insider Activity

In other news, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the transaction, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. This trade represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Nano Cap New Millennium Growth Fund L P acquired a new stake in Janux Therapeutics during the 4th quarter valued at $34,000. Versant Capital Management Inc increased its position in Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after buying an additional 784 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Janux Therapeutics in the fourth quarter worth $51,000. Osaic Holdings Inc. raised its holdings in shares of Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares during the last quarter. Finally, Quantbot Technologies LP lifted its position in shares of Janux Therapeutics by 2,290.0% in the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock valued at $84,000 after acquiring an additional 5,267 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.